130 related articles for article (PubMed ID: 35621706)
1. Flucytosine-based prodrug activation by cold physical plasma.
Ahmadi M; Potlitz F; Link A; von Woedtke T; Nasri Z; Wende K
Arch Pharm (Weinheim); 2022 Sep; 355(9):e2200061. PubMed ID: 35621706
[TBL] [Abstract][Full Text] [Related]
2. Cold Physical Plasma-Mediated Fenretinide Prodrug Activation Confers Additive Cytotoxicity in Epithelial Cells.
Ahmadi M; Singer D; Potlitz F; Nasri Z; von Woedtke T; Link A; Bekeschus S; Wende K
Antioxidants (Basel); 2023 Jun; 12(6):. PubMed ID: 37372001
[TBL] [Abstract][Full Text] [Related]
3. ROS-triggered cycle amplification effect: A prodrug activation nanoamplifier for tumor-specific therapy.
Huang Z; Ding Y; Luo Y; Chen M; Zeng Z; Zhang T; Sun Y; Huang Y; Zhao C
Acta Biomater; 2022 Oct; 152():367-379. PubMed ID: 36084924
[TBL] [Abstract][Full Text] [Related]
4. Auxiliary in vitro and in vivo biological evaluation of hydrogen peroxide sensitive prodrugs of methotrexate and aminopterin for the treatment of rheumatoid arthritis.
Previtali V; Petrovic K; Peiró Cadahía J; Troelsen NS; Clausen MH
Bioorg Med Chem; 2020 Jan; 28(2):115247. PubMed ID: 31843461
[TBL] [Abstract][Full Text] [Related]
5. Self-Strengthened Oxidation-Responsive Bioactivating Prodrug Nanosystem with Sequential and Synergistically Facilitated Drug Release for Treatment of Breast Cancer.
Wang K; Yang B; Ye H; Zhang X; Song H; Wang X; Li N; Wei L; Wang Y; Zhang H; Kan Q; He Z; Wang D; Sun J
ACS Appl Mater Interfaces; 2019 May; 11(21):18914-18922. PubMed ID: 31055911
[TBL] [Abstract][Full Text] [Related]
6. Lysosome-Targeting Amplifiers of Reactive Oxygen Species as Anticancer Prodrugs.
Daum S; Reshetnikov MSV; Sisa M; Dumych T; Lootsik MD; Bilyy R; Bila E; Janko C; Alexiou C; Herrmann M; Sellner L; Mokhir A
Angew Chem Int Ed Engl; 2017 Dec; 56(49):15545-15549. PubMed ID: 28994179
[TBL] [Abstract][Full Text] [Related]
7. Isocytosine deaminase Vcz as a novel tool for the prodrug cancer therapy.
Kazlauskas A; Darinskas A; Meškys R; Tamašauskas A; Urbonavičius J
BMC Cancer; 2019 Mar; 19(1):197. PubMed ID: 30832616
[TBL] [Abstract][Full Text] [Related]
8. Allyl phenyl selenides as H
Yang XY; Yuan B; Xiong H; Zhao Y; Wang L; Zhang SQ; Mao S
Bioorg Chem; 2022 Dec; 129():106154. PubMed ID: 36137311
[TBL] [Abstract][Full Text] [Related]
9. Anticancer boron-containing prodrugs responsive to oxidative stress from the tumor microenvironment.
Maslah H; Skarbek C; Pethe S; Labruère R
Eur J Med Chem; 2020 Dec; 207():112670. PubMed ID: 32858470
[TBL] [Abstract][Full Text] [Related]
10. pH/ROS dual-responsive supramolecular polypeptide prodrug nanomedicine based on host-guest recognition for cancer therapy.
Ding Y; Wang C; Ma Y; Zhu L; Lu B; Wang Y; Wang J; Chen T; Dong CM; Yao Y
Acta Biomater; 2022 Apr; 143():381-391. PubMed ID: 35272024
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and Evaluation of Reactive Oxygen Species Sensitive Prodrugs of a NAMPT Inhibitor FK866.
Xu Z; Wang H; Liu H; Chen H; Jiang B
Molecules; 2022 Dec; 28(1):. PubMed ID: 36615364
[TBL] [Abstract][Full Text] [Related]
12. Dihydropyrimidine Dehydrogenase Is a Prognostic Marker for Mesenchymal Stem Cell-Mediated Cytosine Deaminase Gene and 5-Fluorocytosine Prodrug Therapy for the Treatment of Recurrent Gliomas.
Chung T; Na J; Kim YI; Chang DY; Kim YI; Kim H; Moon HE; Kang KW; Lee DS; Chung JK; Kim SS; Suh-Kim H; Paek SH; Youn H
Theranostics; 2016; 6(10):1477-90. PubMed ID: 27446484
[TBL] [Abstract][Full Text] [Related]
13. Modified peroxamide-based reactive oxygen species (ROS)-responsive doxorubicin prodrugs.
Jafari M; Sriram V; Premnauth G; Merino E; Lee JY
Bioorg Chem; 2022 Oct; 127():105990. PubMed ID: 35785552
[TBL] [Abstract][Full Text] [Related]
14. Arylboronate prodrugs of doxorubicin as promising chemotherapy for pancreatic cancer.
Skarbek C; Serra S; Maslah H; Rascol E; Labruère R
Bioorg Chem; 2019 Oct; 91():103158. PubMed ID: 31376782
[TBL] [Abstract][Full Text] [Related]
15. Integrated block copolymer prodrug nanoparticles for combination of tumor oxidative stress amplification and ROS-responsive drug release.
Yin W; Ke W; Chen W; Xi L; Zhou Q; Mukerabigwi JF; Ge Z
Biomaterials; 2019 Mar; 195():63-74. PubMed ID: 30612064
[TBL] [Abstract][Full Text] [Related]
16. ROS-Activated homodimeric podophyllotoxin nanomedicine with self-accelerating drug release for efficient cancer eradication.
Liang B; Zhou D
Drug Deliv; 2021 Dec; 28(1):2361-2372. PubMed ID: 34747277
[TBL] [Abstract][Full Text] [Related]
17. ROS-responsive "smart" polymeric conjugate: Synthesis, characterization and proof-of-concept study.
Oddone N; Pederzoli F; Duskey JT; De Benedictis CA; Grabrucker AM; Forni F; Angela Vandelli M; Ruozi B; Tosi G
Int J Pharm; 2019 Oct; 570():118655. PubMed ID: 31479731
[TBL] [Abstract][Full Text] [Related]
18. Adipose tissue-derived human mesenchymal stem cells mediated prodrug cancer gene therapy.
Kucerova L; Altanerova V; Matuskova M; Tyciakova S; Altaner C
Cancer Res; 2007 Jul; 67(13):6304-13. PubMed ID: 17616689
[TBL] [Abstract][Full Text] [Related]
19. Influence of the prodrugs 5-fluorocytosine and CPT-11 on ovarian cancer cells using genetically engineered stem cells: tumor-tropic potential and inhibition of ovarian cancer cell growth.
Kim KY; Kim SU; Leung PC; Jeung EB; Choi KC
Cancer Sci; 2010 Apr; 101(4):955-62. PubMed ID: 20704576
[TBL] [Abstract][Full Text] [Related]
20. Design, construction, and in vitro analysis of A33scFv::CDy, a recombinant fusion protein for antibody-directed enzyme prodrug therapy in colon cancer.
Coelho V; Dernedde J; Petrausch U; Panjideh H; Fuchs H; Menzel C; Dübel S; Keilholz U; Thiel E; Deckert PM
Int J Oncol; 2007 Oct; 31(4):951-7. PubMed ID: 17786329
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
